Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer | Zendy

Dennis J. Slamon | Zendy; Patrick Neven | Zendy; Stephen Chia | Zendy; Peter A. Fasching | Zendy; Michelino De Laurentiis | Zendy; SeockAh Im | Zendy; Katarína Petráková | Zendy; Giulia Bianchi | Zendy; Francisco J. Esteva | Zendy; Miguel Martín | Zendy; Arnd Nusch | Zendy; Gabe S. Sonke | Zendy; Luis de la CruzMerino | Zendy; J. Thaddeus Beck | Zendy; Xavier Pivot | Zendy; Manu Sondhi | Zendy; Yingbo Wang | Zendy; Arunava Chakravartty | Zendy; Karen Rodriguez-Lorenc | Zendy; Tetiana Taran | Zendy; Guy Jérusalem | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer

Author(s) -

Dennis J. Slamon,

Patrick Neven,

Stephen Chia,

Peter A. Fasching,

Michelino De Laurentiis,

SeockAh Im,

Katarína Petráková,

Giulia Bianchi,

Francisco J. Esteva,

Miguel Martín,

Arnd Nusch,

Gabe S. Sonke,

Luis de la CruzMerino,

J. Thaddeus Beck,

Xavier Pivot,

Manu Sondhi,

Yingbo Wang,

Arunava Chakravartty,

Karen Rodriguez-Lorenc,

Tetiana Taran,

Guy Jérusalem

Publication year - 2019

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1911149

Subject(s) - fulvestrant , oncology , medicine , interim analysis , cancer , breast cancer , human epidermal growth factor receptor 2 , hormone receptor , metastatic breast cancer , clinical trial , estrogen receptor

In an earlier analysis of this phase 3 trial, ribociclib plus fulvestrant showed a greater benefit with regard to progression-free survival than fulvestrant alone in postmenopausal patients with hormone-receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer. Here we report the results of a protocol-specified second interim analysis of overall survival.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research